| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macrophages, Alveolar | 11 | 2025 | 66 | 5.250 |
Why?
|
| Pulmonary Alveoli | 26 | 2016 | 72 | 4.630 |
Why?
|
| Lung | 31 | 2021 | 1384 | 4.550 |
Why?
|
| Particulate Matter | 15 | 2020 | 124 | 4.470 |
Why?
|
| Fibroblasts | 13 | 2021 | 777 | 3.490 |
Why?
|
| Acute Lung Injury | 9 | 2019 | 68 | 3.190 |
Why?
|
| Mitochondria | 13 | 2025 | 622 | 3.170 |
Why?
|
| Air Pollutants | 8 | 2020 | 109 | 2.830 |
Why?
|
| Air Pollution | 8 | 2020 | 107 | 2.500 |
Why?
|
| Transforming Growth Factor beta | 11 | 2020 | 349 | 2.460 |
Why?
|
| Pulmonary Fibrosis | 9 | 2019 | 152 | 2.220 |
Why?
|
| Lung Diseases | 7 | 2018 | 290 | 2.000 |
Why?
|
| Pulmonary Edema | 9 | 2019 | 54 | 1.990 |
Why?
|
| Collagen | 7 | 2021 | 306 | 1.980 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 6 | 2019 | 210 | 1.860 |
Why?
|
| Mice, Inbred C57BL | 32 | 2025 | 3489 | 1.850 |
Why?
|
| Orthomyxoviridae Infections | 5 | 2018 | 57 | 1.820 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2025 | 170 | 1.790 |
Why?
|
| Animals | 78 | 2025 | 28891 | 1.770 |
Why?
|
| Myofibroblasts | 4 | 2021 | 51 | 1.740 |
Why?
|
| Reactive Oxygen Species | 18 | 2020 | 517 | 1.730 |
Why?
|
| Cells, Cultured | 20 | 2021 | 2939 | 1.700 |
Why?
|
| Mice | 48 | 2025 | 12537 | 1.670 |
Why?
|
| Glycolysis | 8 | 2025 | 191 | 1.540 |
Why?
|
| Fibrosis | 5 | 2021 | 235 | 1.530 |
Why?
|
| Respiratory Mucosa | 5 | 2021 | 90 | 1.520 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 10 | 2016 | 89 | 1.500 |
Why?
|
| Endothelium, Vascular | 6 | 2021 | 437 | 1.450 |
Why?
|
| Inflammation | 10 | 2020 | 1063 | 1.440 |
Why?
|
| Epithelial Cells | 11 | 2019 | 705 | 1.350 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 4 | 2014 | 27 | 1.330 |
Why?
|
| Cell Differentiation | 7 | 2021 | 1667 | 1.260 |
Why?
|
| Endothelial Cells | 6 | 2021 | 477 | 1.240 |
Why?
|
| Interleukin-6 | 8 | 2018 | 281 | 1.240 |
Why?
|
| Humans | 109 | 2021 | 96105 | 1.220 |
Why?
|
| Albuterol | 4 | 2014 | 35 | 1.220 |
Why?
|
| Kruppel-Like Transcription Factors | 2 | 2021 | 109 | 1.160 |
Why?
|
| Hypoxia | 7 | 2017 | 681 | 1.160 |
Why?
|
| Receptors, Adrenergic, beta-2 | 7 | 2007 | 39 | 1.160 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2014 | 115 | 1.160 |
Why?
|
| Bleomycin | 9 | 2019 | 103 | 1.160 |
Why?
|
| Lung Injury | 7 | 2014 | 60 | 1.110 |
Why?
|
| Thrombosis | 3 | 2018 | 326 | 1.100 |
Why?
|
| Phosphoglycerate Dehydrogenase | 2 | 2018 | 8 | 1.070 |
Why?
|
| Sodium | 7 | 2012 | 340 | 1.050 |
Why?
|
| Alveolar Epithelial Cells | 3 | 2019 | 18 | 1.030 |
Why?
|
| Influenza A virus | 3 | 2018 | 177 | 1.000 |
Why?
|
| Leptin | 3 | 2014 | 102 | 1.000 |
Why?
|
| Disease Models, Animal | 16 | 2019 | 2534 | 1.000 |
Why?
|
| Signal Transduction | 16 | 2020 | 3581 | 1.000 |
Why?
|
| Male | 59 | 2021 | 45863 | 0.990 |
Why?
|
| Macrophages | 4 | 2025 | 623 | 0.950 |
Why?
|
| Bronchoalveolar Lavage | 3 | 2015 | 27 | 0.950 |
Why?
|
| Transforming Growth Factor beta1 | 6 | 2019 | 89 | 0.940 |
Why?
|
| Mice, Knockout | 16 | 2020 | 2161 | 0.920 |
Why?
|
| Oxygen | 6 | 2020 | 781 | 0.910 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2011 | 72 | 0.890 |
Why?
|
| Gene Transfer Techniques | 6 | 2007 | 156 | 0.880 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2019 | 306 | 0.860 |
Why?
|
| Iron | 2 | 2015 | 179 | 0.820 |
Why?
|
| Glutamine | 3 | 2019 | 99 | 0.810 |
Why?
|
| Asthma | 6 | 2015 | 1051 | 0.800 |
Why?
|
| Bronchoalveolar Lavage Fluid | 11 | 2014 | 133 | 0.800 |
Why?
|
| Rats | 20 | 2017 | 4155 | 0.790 |
Why?
|
| Serine | 3 | 2020 | 108 | 0.790 |
Why?
|
| Scleroderma, Systemic | 3 | 2012 | 59 | 0.780 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2014 | 93 | 0.770 |
Why?
|
| Aging | 2 | 2021 | 766 | 0.770 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2014 | 46 | 0.760 |
Why?
|
| Macrophage Activation | 2 | 2020 | 52 | 0.740 |
Why?
|
| Electron Transport Complex I | 2 | 2020 | 34 | 0.730 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2017 | 220 | 0.730 |
Why?
|
| Oxidative Stress | 3 | 2014 | 473 | 0.730 |
Why?
|
| Perioperative Care | 2 | 2014 | 188 | 0.730 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2020 | 51 | 0.720 |
Why?
|
| Geotrichosis | 1 | 2021 | 1 | 0.720 |
Why?
|
| Rats, Sprague-Dawley | 14 | 2017 | 1267 | 0.700 |
Why?
|
| Glucose Transporter Type 3 | 1 | 2021 | 4 | 0.700 |
Why?
|
| Pneumonia | 5 | 2012 | 197 | 0.700 |
Why?
|
| Energy Metabolism | 2 | 2021 | 312 | 0.700 |
Why?
|
| Hyperoxia | 5 | 2012 | 37 | 0.680 |
Why?
|
| Respiration, Artificial | 6 | 2010 | 424 | 0.680 |
Why?
|
| Cellular Microenvironment | 1 | 2021 | 30 | 0.680 |
Why?
|
| Hydrogen Peroxide | 2 | 2020 | 165 | 0.670 |
Why?
|
| Hypercapnia | 4 | 2010 | 49 | 0.670 |
Why?
|
| beta Catenin | 3 | 2014 | 266 | 0.670 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2020 | 20 | 0.670 |
Why?
|
| Apoptosis | 6 | 2013 | 1756 | 0.670 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 45 | 0.660 |
Why?
|
| Molecular Imaging | 1 | 2021 | 72 | 0.650 |
Why?
|
| Occupational Diseases | 2 | 2011 | 57 | 0.650 |
Why?
|
| Succinates | 1 | 2020 | 25 | 0.640 |
Why?
|
| Carboxy-Lyases | 1 | 2020 | 22 | 0.640 |
Why?
|
| Amino Acids | 1 | 2021 | 262 | 0.640 |
Why?
|
| Mycoses | 1 | 2020 | 47 | 0.640 |
Why?
|
| Inhalation Exposure | 2 | 2018 | 33 | 0.640 |
Why?
|
| Gene Expression Regulation | 8 | 2017 | 2061 | 0.640 |
Why?
|
| Myocardial Stunning | 1 | 2020 | 12 | 0.640 |
Why?
|
| Heart Arrest | 2 | 2020 | 312 | 0.630 |
Why?
|
| Critical Illness | 5 | 2013 | 346 | 0.630 |
Why?
|
| Superoxides | 1 | 2020 | 76 | 0.620 |
Why?
|
| Glutaminase | 1 | 2019 | 14 | 0.620 |
Why?
|
| Metformin | 2 | 2018 | 125 | 0.620 |
Why?
|
| Pseudomonas Infections | 2 | 2013 | 95 | 0.610 |
Why?
|
| Biocompatible Materials | 2 | 2011 | 201 | 0.610 |
Why?
|
| Critical Care Nursing | 1 | 2019 | 5 | 0.610 |
Why?
|
| Blood Coagulation | 2 | 2011 | 90 | 0.600 |
Why?
|
| Capillary Permeability | 2 | 2017 | 132 | 0.600 |
Why?
|
| Cell Line | 10 | 2018 | 2537 | 0.590 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 205 | 0.590 |
Why?
|
| Bacterial Infections | 1 | 2020 | 185 | 0.590 |
Why?
|
| DNA, Mitochondrial | 2 | 2016 | 197 | 0.580 |
Why?
|
| Female | 34 | 2021 | 50028 | 0.580 |
Why?
|
| DNA Glycosylases | 2 | 2016 | 25 | 0.570 |
Why?
|
| Behavior Therapy | 1 | 2019 | 95 | 0.570 |
Why?
|
| Airway Remodeling | 1 | 2018 | 10 | 0.560 |
Why?
|
| Lipopolysaccharides | 5 | 2020 | 305 | 0.550 |
Why?
|
| Glucose | 1 | 2021 | 701 | 0.550 |
Why?
|
| Endothelin-1 | 1 | 2017 | 41 | 0.540 |
Why?
|
| DNA Damage | 2 | 2016 | 392 | 0.530 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 259 | 0.530 |
Why?
|
| Phosphofructokinase-2 | 1 | 2017 | 2 | 0.520 |
Why?
|
| Monocytes | 2 | 2017 | 231 | 0.520 |
Why?
|
| Mediastinal Cyst | 1 | 2016 | 3 | 0.510 |
Why?
|
| Intra-Abdominal Fat | 1 | 2017 | 34 | 0.510 |
Why?
|
| Regional Blood Flow | 1 | 2017 | 197 | 0.510 |
Why?
|
| Glycine Hydroxymethyltransferase | 1 | 2016 | 5 | 0.510 |
Why?
|
| Oxidants | 3 | 2013 | 86 | 0.510 |
Why?
|
| Burns | 1 | 2019 | 150 | 0.510 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2016 | 52 | 0.510 |
Why?
|
| Stem Cells | 1 | 2019 | 394 | 0.500 |
Why?
|
| Pleura | 1 | 2016 | 32 | 0.500 |
Why?
|
| GTP Phosphohydrolases | 1 | 2017 | 82 | 0.500 |
Why?
|
| Sirtuin 3 | 1 | 2016 | 36 | 0.490 |
Why?
|
| Cardiac Glycosides | 1 | 2016 | 5 | 0.490 |
Why?
|
| Adenoviridae | 7 | 2011 | 342 | 0.490 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2016 | 27 | 0.480 |
Why?
|
| Digoxin | 1 | 2016 | 21 | 0.480 |
Why?
|
| Paracrine Communication | 1 | 2016 | 32 | 0.480 |
Why?
|
| Ouabain | 1 | 2016 | 25 | 0.480 |
Why?
|
| Down-Regulation | 3 | 2016 | 526 | 0.480 |
Why?
|
| Keratinocytes | 1 | 2017 | 146 | 0.480 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2015 | 5 | 0.480 |
Why?
|
| Electron Transport Complex III | 4 | 2012 | 13 | 0.480 |
Why?
|
| Respiratory Insufficiency | 4 | 2010 | 205 | 0.470 |
Why?
|
| Wood | 1 | 2015 | 23 | 0.470 |
Why?
|
| Smoke | 1 | 2015 | 29 | 0.470 |
Why?
|
| Transglutaminases | 1 | 2015 | 41 | 0.460 |
Why?
|
| Pneumothorax | 1 | 2015 | 52 | 0.460 |
Why?
|
| Asbestos, Crocidolite | 1 | 2015 | 2 | 0.450 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 656 | 0.450 |
Why?
|
| Influenza, Human | 2 | 2018 | 370 | 0.450 |
Why?
|
| Receptor, Adenosine A1 | 2 | 2012 | 8 | 0.450 |
Why?
|
| Flow Cytometry | 2 | 2013 | 728 | 0.440 |
Why?
|
| GTP-Binding Proteins | 1 | 2015 | 148 | 0.440 |
Why?
|
| Emphysema | 1 | 2015 | 24 | 0.440 |
Why?
|
| Antigens, Ly | 1 | 2014 | 37 | 0.440 |
Why?
|
| Interferon Type I | 1 | 2016 | 206 | 0.440 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-5 | 1 | 2014 | 4 | 0.440 |
Why?
|
| Arthritis, Experimental | 1 | 2014 | 27 | 0.430 |
Why?
|
| Adrenergic beta-Agonists | 3 | 2007 | 75 | 0.430 |
Why?
|
| Hemorrhagic Disorders | 1 | 2014 | 2 | 0.430 |
Why?
|
| Serpin E2 | 1 | 2014 | 4 | 0.430 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 1021 | 0.430 |
Why?
|
| Proteasome Inhibitors | 2 | 2011 | 54 | 0.430 |
Why?
|
| Boronic Acids | 2 | 2011 | 55 | 0.430 |
Why?
|
| Membrane Proteins | 3 | 2017 | 1276 | 0.430 |
Why?
|
| Babesiosis | 1 | 2014 | 4 | 0.430 |
Why?
|
| Hypertension, Pulmonary | 1 | 2018 | 381 | 0.420 |
Why?
|
| Ion Transport | 5 | 2012 | 87 | 0.420 |
Why?
|
| Glucuronidase | 1 | 2014 | 25 | 0.420 |
Why?
|
| Gastrointestinal Tract | 2 | 2018 | 197 | 0.420 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2014 | 83 | 0.420 |
Why?
|
| Pyrazines | 2 | 2011 | 94 | 0.420 |
Why?
|
| Bronchoscopy | 1 | 2015 | 178 | 0.410 |
Why?
|
| Th17 Cells | 1 | 2014 | 97 | 0.410 |
Why?
|
| PPAR gamma | 2 | 2011 | 76 | 0.410 |
Why?
|
| Th2 Cells | 1 | 2014 | 151 | 0.410 |
Why?
|
| Antiviral Agents | 2 | 2020 | 504 | 0.410 |
Why?
|
| Nitric Oxide | 1 | 2015 | 281 | 0.400 |
Why?
|
| Transcriptome | 1 | 2019 | 769 | 0.400 |
Why?
|
| Silicon Dioxide | 1 | 2013 | 39 | 0.400 |
Why?
|
| CCAAT-Enhancer-Binding Protein-delta | 1 | 2013 | 4 | 0.400 |
Why?
|
| Pulmonary Embolism | 2 | 2006 | 235 | 0.400 |
Why?
|
| Particle Size | 5 | 2011 | 126 | 0.400 |
Why?
|
| Protein Inhibitors of Activated STAT | 1 | 2013 | 6 | 0.400 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2014 | 151 | 0.400 |
Why?
|
| Pneumonia, Viral | 2 | 2018 | 346 | 0.400 |
Why?
|
| Critical Care | 4 | 2021 | 447 | 0.400 |
Why?
|
| Trachea | 2 | 2014 | 293 | 0.390 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 163 | 0.390 |
Why?
|
| Blotting, Western | 5 | 2017 | 796 | 0.380 |
Why?
|
| Receptors, Adrenergic, beta | 3 | 2014 | 73 | 0.380 |
Why?
|
| Postoperative Complications | 2 | 2014 | 2591 | 0.380 |
Why?
|
| 5-Hydroxytryptophan | 1 | 2012 | 5 | 0.380 |
Why?
|
| Muscle Hypotonia | 2 | 2010 | 49 | 0.380 |
Why?
|
| Environmental Exposure | 2 | 2018 | 357 | 0.370 |
Why?
|
| Bronchi | 1 | 2013 | 234 | 0.370 |
Why?
|
| Antioxidants | 3 | 2009 | 232 | 0.370 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2010 | 67 | 0.370 |
Why?
|
| Antibodies, Viral | 1 | 2014 | 348 | 0.370 |
Why?
|
| Fluorobenzenes | 1 | 2012 | 34 | 0.370 |
Why?
|
| Cell Membrane Permeability | 2 | 2014 | 121 | 0.360 |
Why?
|
| Gastrointestinal Diseases | 3 | 2003 | 154 | 0.360 |
Why?
|
| Cytokines | 7 | 2018 | 871 | 0.360 |
Why?
|
| Biomarkers | 5 | 2021 | 1930 | 0.360 |
Why?
|
| Graphite | 1 | 2011 | 13 | 0.360 |
Why?
|
| Poloxamer | 1 | 2011 | 29 | 0.360 |
Why?
|
| Salicylates | 2 | 2009 | 25 | 0.360 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2012 | 87 | 0.360 |
Why?
|
| Mice, Transgenic | 5 | 2021 | 1645 | 0.350 |
Why?
|
| Gene Expression | 4 | 2016 | 1320 | 0.350 |
Why?
|
| Cell Movement | 5 | 2021 | 816 | 0.350 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2013 | 202 | 0.350 |
Why?
|
| Middle Aged | 16 | 2020 | 28368 | 0.350 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 590 | 0.340 |
Why?
|
| Oxygen Consumption | 2 | 2020 | 253 | 0.340 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 3 | 2007 | 57 | 0.340 |
Why?
|
| Reflex, Abnormal | 1 | 2010 | 7 | 0.330 |
Why?
|
| Hypersensitivity | 1 | 2012 | 166 | 0.330 |
Why?
|
| Spinocerebellar Degenerations | 1 | 2010 | 19 | 0.330 |
Why?
|
| Organometallic Compounds | 2 | 2009 | 148 | 0.330 |
Why?
|
| Tracheitis | 1 | 2010 | 3 | 0.330 |
Why?
|
| Sleep Apnea, Central | 1 | 2010 | 15 | 0.330 |
Why?
|
| Nanotubes | 1 | 2010 | 10 | 0.320 |
Why?
|
| Coma | 1 | 2010 | 52 | 0.320 |
Why?
|
| Cardiovascular Diseases | 3 | 2011 | 777 | 0.320 |
Why?
|
| Calcium Channels | 1 | 2011 | 183 | 0.320 |
Why?
|
| Mediastinal Emphysema | 1 | 2010 | 6 | 0.320 |
Why?
|
| Enzyme Activation | 4 | 2016 | 692 | 0.320 |
Why?
|
| Helium | 1 | 2010 | 13 | 0.320 |
Why?
|
| TCF Transcription Factors | 1 | 2009 | 26 | 0.310 |
Why?
|
| Protease Inhibitors | 1 | 2010 | 72 | 0.310 |
Why?
|
| Sulfonamides | 1 | 2012 | 337 | 0.310 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 2 | 2007 | 14 | 0.310 |
Why?
|
| Brain Stem | 1 | 2010 | 170 | 0.310 |
Why?
|
| Oxidative Phosphorylation | 3 | 2020 | 64 | 0.310 |
Why?
|
| Epithelium | 5 | 2016 | 322 | 0.310 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 112 | 0.310 |
Why?
|
| Pyrimidines | 1 | 2012 | 386 | 0.300 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2009 | 10 | 0.300 |
Why?
|
| Ubiquitin | 1 | 2010 | 95 | 0.300 |
Why?
|
| Ethanol | 1 | 2012 | 270 | 0.300 |
Why?
|
| Glycine | 2 | 2020 | 96 | 0.300 |
Why?
|
| Intellectual Disability | 1 | 2010 | 203 | 0.300 |
Why?
|
| Dendritic Cells | 1 | 2013 | 541 | 0.300 |
Why?
|
| Hypnotics and Sedatives | 1 | 2010 | 142 | 0.300 |
Why?
|
| Adult | 16 | 2021 | 28721 | 0.300 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2008 | 3 | 0.300 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 180 | 0.290 |
Why?
|
| Developmental Disabilities | 1 | 2010 | 208 | 0.290 |
Why?
|
| Dystroglycans | 1 | 2008 | 15 | 0.290 |
Why?
|
| Pyridines | 1 | 2010 | 319 | 0.280 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 113 | 0.280 |
Why?
|
| Cell Proliferation | 4 | 2018 | 1753 | 0.280 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 750 | 0.280 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 395 | 0.280 |
Why?
|
| Adenosine | 2 | 2012 | 278 | 0.280 |
Why?
|
| Carotid Artery Thrombosis | 1 | 2007 | 5 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2009 | 207 | 0.270 |
Why?
|
| Neoplasms | 2 | 2021 | 3248 | 0.270 |
Why?
|
| Electrochemotherapy | 1 | 2007 | 4 | 0.270 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 465 | 0.270 |
Why?
|
| Ventilator-Induced Lung Injury | 2 | 2021 | 33 | 0.260 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2011 | 713 | 0.260 |
Why?
|
| Aged | 11 | 2020 | 20968 | 0.260 |
Why?
|
| Positive-Pressure Respiration | 3 | 2011 | 50 | 0.260 |
Why?
|
| Sclerosing Solutions | 1 | 2006 | 5 | 0.260 |
Why?
|
| Talc | 1 | 2006 | 4 | 0.260 |
Why?
|
| Genetic Vectors | 4 | 2002 | 446 | 0.260 |
Why?
|
| Pleurodesis | 1 | 2006 | 9 | 0.260 |
Why?
|
| Pulmonary Surfactants | 3 | 2004 | 22 | 0.250 |
Why?
|
| Models, Biological | 4 | 2021 | 1809 | 0.250 |
Why?
|
| Mice, Mutant Strains | 3 | 2013 | 232 | 0.250 |
Why?
|
| Dietary Proteins | 1 | 2006 | 31 | 0.250 |
Why?
|
| Alanine Transaminase | 1 | 2006 | 73 | 0.240 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2006 | 52 | 0.240 |
Why?
|
| Aspartate Aminotransferases | 1 | 2006 | 75 | 0.240 |
Why?
|
| Hospital Mortality | 1 | 2009 | 483 | 0.240 |
Why?
|
| Genes, p53 | 1 | 2006 | 109 | 0.240 |
Why?
|
| Bone Cements | 1 | 2006 | 11 | 0.240 |
Why?
|
| Extravascular Lung Water | 1 | 2006 | 5 | 0.240 |
Why?
|
| Polymethyl Methacrylate | 1 | 2006 | 17 | 0.240 |
Why?
|
| Sarcoidosis | 1 | 2006 | 75 | 0.240 |
Why?
|
| Splenic Diseases | 1 | 2006 | 14 | 0.240 |
Why?
|
| Histoplasma | 1 | 2006 | 16 | 0.240 |
Why?
|
| Serum Albumin | 1 | 2006 | 128 | 0.240 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2006 | 74 | 0.240 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 2005 | 11 | 0.230 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2017 | 76 | 0.230 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2017 | 299 | 0.230 |
Why?
|
| Histoplasmosis | 1 | 2006 | 28 | 0.230 |
Why?
|
| Bacteremia | 1 | 2006 | 108 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2013 | 1973 | 0.230 |
Why?
|
| Confusion | 1 | 2005 | 9 | 0.230 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2005 | 56 | 0.220 |
Why?
|
| Leukemia, Lymphoid | 1 | 2005 | 71 | 0.220 |
Why?
|
| West Nile Fever | 1 | 2005 | 22 | 0.220 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 7229 | 0.220 |
Why?
|
| Paralysis | 1 | 2005 | 34 | 0.220 |
Why?
|
| Receptors, Adrenergic, beta-1 | 3 | 2014 | 8 | 0.220 |
Why?
|
| Interleukin-8 | 2 | 2015 | 88 | 0.220 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2006 | 294 | 0.220 |
Why?
|
| Antibodies | 1 | 2006 | 356 | 0.220 |
Why?
|
| Osteoporosis | 1 | 2006 | 131 | 0.220 |
Why?
|
| Lypressin | 1 | 2004 | 1 | 0.220 |
Why?
|
| Body Weight | 2 | 2017 | 460 | 0.220 |
Why?
|
| Calcinosis | 1 | 2006 | 232 | 0.210 |
Why?
|
| Oximetry | 1 | 2005 | 90 | 0.210 |
Why?
|
| Cell Death | 3 | 2011 | 264 | 0.210 |
Why?
|
| Vasopressins | 1 | 2004 | 50 | 0.210 |
Why?
|
| Mice, Inbred BALB C | 3 | 2012 | 1124 | 0.210 |
Why?
|
| Cellular Senescence | 2 | 2015 | 106 | 0.210 |
Why?
|
| Vasoconstrictor Agents | 1 | 2004 | 68 | 0.210 |
Why?
|
| Chemokines | 2 | 2015 | 77 | 0.200 |
Why?
|
| RNA, Messenger | 5 | 2013 | 2090 | 0.200 |
Why?
|
| Titrimetry | 1 | 2003 | 15 | 0.200 |
Why?
|
| Laminin | 2 | 2015 | 92 | 0.200 |
Why?
|
| Shock, Septic | 1 | 2004 | 125 | 0.190 |
Why?
|
| Long-Term Care | 1 | 2003 | 63 | 0.190 |
Why?
|
| Carcinoma | 1 | 2006 | 448 | 0.190 |
Why?
|
| Mice, Inbred C3H | 2 | 2014 | 372 | 0.190 |
Why?
|
| Sodium Cyanide | 1 | 2002 | 6 | 0.190 |
Why?
|
| Gastric Mucosa | 1 | 2003 | 70 | 0.190 |
Why?
|
| Fluorocarbon Polymers | 1 | 2002 | 3 | 0.190 |
Why?
|
| Cell Count | 2 | 2017 | 203 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2016 | 2777 | 0.190 |
Why?
|
| Poisoning | 1 | 2002 | 42 | 0.190 |
Why?
|
| Phosphorylation | 2 | 2016 | 1157 | 0.190 |
Why?
|
| Hypokalemia | 1 | 2002 | 24 | 0.190 |
Why?
|
| Soccer | 1 | 2002 | 19 | 0.190 |
Why?
|
| Quadriplegia | 1 | 2002 | 33 | 0.190 |
Why?
|
| Thoracic Surgery, Video-Assisted | 2 | 2016 | 34 | 0.190 |
Why?
|
| Genetic Therapy | 1 | 2004 | 382 | 0.180 |
Why?
|
| Status Asthmaticus | 1 | 2002 | 9 | 0.180 |
Why?
|
| Anesthesia, Inhalation | 1 | 2002 | 37 | 0.180 |
Why?
|
| Pleural Effusion | 2 | 2015 | 46 | 0.180 |
Why?
|
| Stress, Physiological | 2 | 2020 | 252 | 0.180 |
Why?
|
| Geotrichum | 1 | 2021 | 1 | 0.180 |
Why?
|
| Emergencies | 1 | 2002 | 124 | 0.180 |
Why?
|
| Neutrophils | 3 | 2014 | 332 | 0.180 |
Why?
|
| Breath Tests | 1 | 2001 | 58 | 0.180 |
Why?
|
| Receptors, Leptin | 2 | 2014 | 33 | 0.170 |
Why?
|
| Mechanical Phenomena | 1 | 2021 | 17 | 0.170 |
Why?
|
| Autopsy | 1 | 2021 | 129 | 0.170 |
Why?
|
| Tachycardia, Ventricular | 1 | 2002 | 132 | 0.170 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2021 | 88 | 0.170 |
Why?
|
| Antifungal Agents | 1 | 2021 | 126 | 0.170 |
Why?
|
| Random Allocation | 2 | 2020 | 325 | 0.170 |
Why?
|
| Bortezomib | 2 | 2011 | 82 | 0.170 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2020 | 21 | 0.160 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 147 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 380 | 0.160 |
Why?
|
| Retrospective Studies | 6 | 2020 | 10287 | 0.160 |
Why?
|
| Laryngismus | 1 | 2000 | 3 | 0.160 |
Why?
|
| Suicide | 1 | 2002 | 162 | 0.160 |
Why?
|
| Salmeterol Xinafoate | 2 | 2014 | 16 | 0.160 |
Why?
|
| Edetic Acid | 1 | 2000 | 42 | 0.160 |
Why?
|
| Survival Analysis | 3 | 2012 | 1546 | 0.160 |
Why?
|
| Bronchoconstriction | 1 | 2000 | 56 | 0.160 |
Why?
|
| Biological Transport, Active | 3 | 2005 | 105 | 0.160 |
Why?
|
| Cytoskeleton | 1 | 2021 | 200 | 0.160 |
Why?
|
| Sodium Channels | 4 | 2005 | 131 | 0.160 |
Why?
|
| Biological Products | 1 | 2002 | 179 | 0.150 |
Why?
|
| Respiratory System | 1 | 2020 | 121 | 0.150 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2020 | 284 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 897 | 0.150 |
Why?
|
| NF-kappa B | 2 | 2013 | 469 | 0.150 |
Why?
|
| Intensive Care Units | 3 | 2021 | 460 | 0.150 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 217 | 0.150 |
Why?
|
| Wasting Syndrome | 1 | 2018 | 3 | 0.150 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2018 | 4 | 0.150 |
Why?
|
| Superoxide Dismutase | 2 | 2010 | 156 | 0.150 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 2039 | 0.150 |
Why?
|
| Catecholamines | 2 | 2014 | 92 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 367 | 0.150 |
Why?
|
| Diabetes Mellitus | 1 | 2006 | 771 | 0.150 |
Why?
|
| Myocardial Ischemia | 1 | 2000 | 167 | 0.150 |
Why?
|
| Neoplasm Proteins | 2 | 2013 | 553 | 0.150 |
Why?
|
| Collagen Type I | 2 | 2016 | 74 | 0.150 |
Why?
|
| Electron Transport | 1 | 2018 | 74 | 0.140 |
Why?
|
| Skin | 2 | 2012 | 605 | 0.140 |
Why?
|
| Oncogene Proteins | 1 | 2019 | 65 | 0.140 |
Why?
|
| Cell Line, Tumor | 4 | 2014 | 2778 | 0.140 |
Why?
|
| Spleen | 2 | 2012 | 439 | 0.140 |
Why?
|
| Muscles | 1 | 2018 | 193 | 0.140 |
Why?
|
| NIH 3T3 Cells | 1 | 2018 | 112 | 0.140 |
Why?
|
| Muscle Proteins | 1 | 2018 | 134 | 0.140 |
Why?
|
| Fatty Acids | 1 | 2019 | 153 | 0.140 |
Why?
|
| Phenotype | 2 | 2014 | 2578 | 0.130 |
Why?
|
| Diagnosis, Differential | 3 | 2010 | 1619 | 0.130 |
Why?
|
| Transgenes | 3 | 2002 | 186 | 0.130 |
Why?
|
| Cell Respiration | 1 | 2017 | 21 | 0.130 |
Why?
|
| Computational Biology | 1 | 2021 | 586 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2013 | 2480 | 0.130 |
Why?
|
| Inpatients | 1 | 2020 | 347 | 0.130 |
Why?
|
| Epigenomics | 1 | 2018 | 109 | 0.130 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2017 | 48 | 0.130 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 397 | 0.130 |
Why?
|
| Air | 1 | 2017 | 63 | 0.130 |
Why?
|
| Time Factors | 2 | 2017 | 5580 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 340 | 0.130 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2020 | 248 | 0.130 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 28 | 0.130 |
Why?
|
| Sepsis | 1 | 2021 | 391 | 0.130 |
Why?
|
| Cytoprotection | 1 | 2016 | 51 | 0.130 |
Why?
|
| Neuropeptides | 1 | 2017 | 116 | 0.120 |
Why?
|
| Epidermis | 1 | 2017 | 104 | 0.120 |
Why?
|
| Survival Rate | 2 | 2012 | 1985 | 0.120 |
Why?
|
| Organ Size | 1 | 2017 | 379 | 0.120 |
Why?
|
| Humic Substances | 1 | 2015 | 1 | 0.120 |
Why?
|
| Nerve Tissue Proteins | 1 | 2019 | 515 | 0.120 |
Why?
|
| Cyclooxygenase 2 | 1 | 2016 | 100 | 0.120 |
Why?
|
| Metabolic Syndrome | 1 | 2017 | 123 | 0.120 |
Why?
|
| Swine | 1 | 2017 | 598 | 0.120 |
Why?
|
| Polysomnography | 2 | 2010 | 155 | 0.120 |
Why?
|
| Heart Failure | 1 | 2006 | 1422 | 0.120 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2016 | 112 | 0.120 |
Why?
|
| Cough | 1 | 2015 | 57 | 0.120 |
Why?
|
| Back Pain | 1 | 2015 | 76 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 2 | 2013 | 206 | 0.110 |
Why?
|
| Obesity | 2 | 2017 | 1030 | 0.110 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2015 | 45 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 2 | 2012 | 256 | 0.110 |
Why?
|
| Phosphatidylcholines | 1 | 2015 | 53 | 0.110 |
Why?
|
| Cyclic AMP | 2 | 2007 | 284 | 0.110 |
Why?
|
| Madin Darby Canine Kidney Cells | 1 | 2014 | 23 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2015 | 224 | 0.110 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2014 | 1 | 0.110 |
Why?
|
| Mice, Obese | 1 | 2014 | 49 | 0.110 |
Why?
|
| Eosinophils | 1 | 2015 | 199 | 0.110 |
Why?
|
| Histocytochemistry | 1 | 2014 | 132 | 0.110 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 353 | 0.110 |
Why?
|
| Antithrombin III | 1 | 2014 | 9 | 0.110 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2014 | 86 | 0.110 |
Why?
|
| Insulin Resistance | 1 | 2017 | 380 | 0.110 |
Why?
|
| Colforsin | 1 | 2014 | 75 | 0.110 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2018 | 292 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 307 | 0.110 |
Why?
|
| Oxidation-Reduction | 2 | 2015 | 411 | 0.110 |
Why?
|
| Propranolol | 1 | 2014 | 44 | 0.110 |
Why?
|
| Radiography | 2 | 2006 | 826 | 0.110 |
Why?
|
| Up-Regulation | 2 | 2009 | 740 | 0.110 |
Why?
|
| Transcription, Genetic | 2 | 2011 | 1192 | 0.110 |
Why?
|
| Blood Gas Analysis | 2 | 2005 | 38 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2016 | 269 | 0.110 |
Why?
|
| Hot Temperature | 1 | 2015 | 217 | 0.110 |
Why?
|
| Peptide Hydrolases | 1 | 2014 | 100 | 0.100 |
Why?
|
| Nasal Cavity | 1 | 2014 | 94 | 0.100 |
Why?
|
| Body Fluids | 2 | 2005 | 35 | 0.100 |
Why?
|
| Extracellular Space | 1 | 2014 | 90 | 0.100 |
Why?
|
| Longevity | 1 | 2014 | 60 | 0.100 |
Why?
|
| Adenylyl Cyclases | 1 | 2014 | 106 | 0.100 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1791 | 0.100 |
Why?
|
| Wnt Proteins | 1 | 2014 | 131 | 0.100 |
Why?
|
| Viral Load | 1 | 2014 | 164 | 0.100 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2013 | 32 | 0.100 |
Why?
|
| Cause of Death | 2 | 2018 | 278 | 0.100 |
Why?
|
| Ferritins | 1 | 2013 | 31 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2014 | 107 | 0.100 |
Why?
|
| Proteolysis | 1 | 2014 | 124 | 0.100 |
Why?
|
| Dogs | 1 | 2014 | 719 | 0.100 |
Why?
|
| Enzyme Repression | 1 | 2013 | 2 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 212 | 0.100 |
Why?
|
| Histone Deacetylase 1 | 1 | 2013 | 16 | 0.100 |
Why?
|
| Telomere | 1 | 2014 | 121 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2006 | 564 | 0.100 |
Why?
|
| Cell Nucleus | 1 | 2015 | 623 | 0.100 |
Why?
|
| Cell Adhesion | 2 | 2014 | 433 | 0.100 |
Why?
|
| Cation Transport Proteins | 1 | 2013 | 70 | 0.100 |
Why?
|
| Myeloid Cells | 1 | 2013 | 121 | 0.100 |
Why?
|
| Risk Factors | 3 | 2013 | 5961 | 0.100 |
Why?
|
| Microbiota | 1 | 2018 | 426 | 0.100 |
Why?
|
| Pyroglyphidae | 1 | 2012 | 15 | 0.090 |
Why?
|
| Transduction, Genetic | 2 | 2004 | 162 | 0.090 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2012 | 20 | 0.090 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2013 | 282 | 0.090 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 1828 | 0.090 |
Why?
|
| Hospitalization | 1 | 2018 | 943 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 161 | 0.090 |
Why?
|
| Rosuvastatin Calcium | 1 | 2012 | 31 | 0.090 |
Why?
|
| Ovalbumin | 1 | 2012 | 110 | 0.090 |
Why?
|
| beta-Galactosidase | 2 | 2002 | 70 | 0.090 |
Why?
|
| Carcinogenesis | 1 | 2014 | 235 | 0.090 |
Why?
|
| Interleukin-4 | 1 | 2012 | 136 | 0.090 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 303 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2013 | 185 | 0.090 |
Why?
|
| Autocrine Communication | 1 | 2011 | 21 | 0.090 |
Why?
|
| Staphylococcus aureus | 1 | 2015 | 287 | 0.090 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Kinase | 1 | 2011 | 3 | 0.090 |
Why?
|
| Stromal Interaction Molecule 1 | 1 | 2011 | 11 | 0.090 |
Why?
|
| ORAI1 Protein | 1 | 2011 | 10 | 0.090 |
Why?
|
| Central Nervous System Depressants | 1 | 2012 | 45 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 176 | 0.090 |
Why?
|
| District of Columbia | 1 | 2011 | 19 | 0.090 |
Why?
|
| Ozone | 1 | 2011 | 12 | 0.090 |
Why?
|
| Prognosis | 2 | 2010 | 4028 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 111 | 0.090 |
Why?
|
| Biomass | 1 | 2011 | 43 | 0.090 |
Why?
|
| Leukocytes | 1 | 2012 | 218 | 0.090 |
Why?
|
| Ligands | 1 | 2012 | 478 | 0.090 |
Why?
|
| Occludin | 1 | 2011 | 66 | 0.090 |
Why?
|
| Caco-2 Cells | 1 | 2011 | 125 | 0.090 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2011 | 26 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1535 | 0.090 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2011 | 70 | 0.090 |
Why?
|
| Serotonin | 1 | 2012 | 219 | 0.090 |
Why?
|
| Extracellular Matrix | 1 | 2012 | 255 | 0.090 |
Why?
|
| Adipose Tissue, White | 1 | 2011 | 28 | 0.090 |
Why?
|
| Cyclophilins | 1 | 2010 | 8 | 0.080 |
Why?
|
| Cities | 1 | 2011 | 57 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2014 | 4671 | 0.080 |
Why?
|
| Carbon Monoxide | 1 | 2011 | 98 | 0.080 |
Why?
|
| Luminescent Proteins | 1 | 2011 | 145 | 0.080 |
Why?
|
| Electric Impedance | 1 | 2011 | 112 | 0.080 |
Why?
|
| Fibrin | 1 | 2011 | 87 | 0.080 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2010 | 19 | 0.080 |
Why?
|
| Acute Disease | 2 | 2003 | 872 | 0.080 |
Why?
|
| DNA | 1 | 2016 | 1333 | 0.080 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2010 | 56 | 0.080 |
Why?
|
| Virus Replication | 1 | 2012 | 326 | 0.080 |
Why?
|
| Eye Abnormalities | 1 | 2010 | 41 | 0.080 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 187 | 0.080 |
Why?
|
| Genes, Recessive | 1 | 2010 | 87 | 0.080 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2010 | 14 | 0.080 |
Why?
|
| Nitrogen Dioxide | 1 | 2010 | 19 | 0.080 |
Why?
|
| Aerobiosis | 1 | 2010 | 22 | 0.080 |
Why?
|
| Colloids | 1 | 2010 | 28 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2009 | 301 | 0.080 |
Why?
|
| Chicago | 2 | 2006 | 1506 | 0.080 |
Why?
|
| RNA Interference | 1 | 2011 | 385 | 0.080 |
Why?
|
| Materials Testing | 1 | 2010 | 94 | 0.080 |
Why?
|
| Immune Tolerance | 1 | 2013 | 385 | 0.080 |
Why?
|
| Dysphonia | 1 | 2010 | 6 | 0.080 |
Why?
|
| Tight Junctions | 1 | 2011 | 153 | 0.080 |
Why?
|
| Smad Proteins | 1 | 2010 | 44 | 0.080 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2010 | 36 | 0.080 |
Why?
|
| Phosphoproteins | 1 | 2011 | 263 | 0.080 |
Why?
|
| Life Expectancy | 1 | 2010 | 91 | 0.080 |
Why?
|
| Tidal Volume | 1 | 2010 | 61 | 0.080 |
Why?
|
| HCT116 Cells | 1 | 2010 | 164 | 0.080 |
Why?
|
| Disease Progression | 1 | 2014 | 1562 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 124 | 0.080 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 1010 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2013 | 447 | 0.080 |
Why?
|
| Crystallization | 1 | 2010 | 216 | 0.080 |
Why?
|
| Chest Pain | 1 | 2010 | 48 | 0.080 |
Why?
|
| Climate Change | 1 | 2010 | 62 | 0.080 |
Why?
|
| Endoplasmic Reticulum | 1 | 2011 | 264 | 0.080 |
Why?
|
| Syndrome | 1 | 2010 | 453 | 0.080 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 157 | 0.080 |
Why?
|
| Drug Overdose | 1 | 2010 | 89 | 0.080 |
Why?
|
| HEK293 Cells | 1 | 2011 | 706 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 393 | 0.070 |
Why?
|
| Biopsy | 1 | 2012 | 1220 | 0.070 |
Why?
|
| Estradiol | 1 | 2009 | 255 | 0.070 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2008 | 35 | 0.070 |
Why?
|
| Estrogens | 1 | 2009 | 203 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2009 | 280 | 0.070 |
Why?
|
| Catalytic Domain | 1 | 2009 | 165 | 0.070 |
Why?
|
| Cerebellum | 1 | 2010 | 253 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2009 | 155 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2008 | 68 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 76 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1979 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2009 | 3110 | 0.070 |
Why?
|
| Probability | 1 | 2009 | 365 | 0.070 |
Why?
|
| Nanoparticles | 1 | 2010 | 197 | 0.070 |
Why?
|
| United States | 4 | 2021 | 7768 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 204 | 0.070 |
Why?
|
| Prothrombin Time | 1 | 2007 | 19 | 0.070 |
Why?
|
| Adenosine Triphosphate | 1 | 2009 | 329 | 0.070 |
Why?
|
| Clodronic Acid | 1 | 2007 | 9 | 0.070 |
Why?
|
| Blood Coagulation Factors | 1 | 2007 | 20 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2012 | 591 | 0.070 |
Why?
|
| Cycloheximide | 1 | 2007 | 58 | 0.070 |
Why?
|
| Thrombin | 1 | 2007 | 61 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2015 | 1730 | 0.070 |
Why?
|
| Ferric Compounds | 1 | 2007 | 41 | 0.070 |
Why?
|
| Logistic Models | 2 | 2018 | 1268 | 0.070 |
Why?
|
| Hydrolysis | 1 | 2007 | 146 | 0.070 |
Why?
|
| Stress, Mechanical | 1 | 2008 | 261 | 0.070 |
Why?
|
| Cell Survival | 1 | 2009 | 1030 | 0.070 |
Why?
|
| Chlorides | 1 | 2007 | 108 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2009 | 908 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2007 | 214 | 0.060 |
Why?
|
| Toluene | 1 | 2006 | 6 | 0.060 |
Why?
|
| Benzothiazoles | 1 | 2006 | 17 | 0.060 |
Why?
|
| Plasmids | 1 | 2007 | 291 | 0.060 |
Why?
|
| DNA Fragmentation | 1 | 2006 | 65 | 0.060 |
Why?
|
| Edema | 1 | 2006 | 73 | 0.060 |
Why?
|
| Recurrence | 1 | 2010 | 1218 | 0.060 |
Why?
|
| Calcium | 1 | 2011 | 1205 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 124 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 563 | 0.060 |
Why?
|
| Osmotic Pressure | 1 | 2006 | 21 | 0.060 |
Why?
|
| Electrophysiology | 1 | 2007 | 406 | 0.060 |
Why?
|
| Biological Transport | 1 | 2007 | 412 | 0.060 |
Why?
|
| Barium Sulfate | 1 | 2006 | 41 | 0.060 |
Why?
|
| Physical Fitness | 1 | 2006 | 52 | 0.060 |
Why?
|
| Depression | 1 | 2010 | 560 | 0.060 |
Why?
|
| Hydrostatic Pressure | 1 | 2005 | 5 | 0.060 |
Why?
|
| Absorption | 1 | 2005 | 26 | 0.060 |
Why?
|
| Cystic Fibrosis | 1 | 2007 | 121 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1096 | 0.060 |
Why?
|
| Mediastinal Diseases | 1 | 2006 | 22 | 0.060 |
Why?
|
| Neuroradiography | 1 | 2005 | 3 | 0.060 |
Why?
|
| Medical Records | 1 | 2006 | 126 | 0.060 |
Why?
|
| Translocation, Genetic | 1 | 2006 | 263 | 0.060 |
Why?
|
| Meningitis | 1 | 2005 | 23 | 0.060 |
Why?
|
| Low Back Pain | 1 | 2006 | 59 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 298 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2010 | 9175 | 0.060 |
Why?
|
| Cell Membrane | 2 | 2006 | 695 | 0.060 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 2004 | 13 | 0.060 |
Why?
|
| Fever | 1 | 2006 | 131 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 314 | 0.060 |
Why?
|
| Urban Population | 1 | 2006 | 240 | 0.060 |
Why?
|
| Ventilators, Mechanical | 1 | 2005 | 43 | 0.060 |
Why?
|
| Radiation Pneumonitis | 1 | 2004 | 23 | 0.060 |
Why?
|
| Endothelium | 1 | 2004 | 60 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 1179 | 0.050 |
Why?
|
| Protein Conformation | 1 | 2007 | 935 | 0.050 |
Why?
|
| Spine | 1 | 2006 | 153 | 0.050 |
Why?
|
| Blood Circulation | 1 | 2004 | 31 | 0.050 |
Why?
|
| Amiloride | 1 | 2004 | 36 | 0.050 |
Why?
|
| Electromyography | 1 | 2005 | 201 | 0.050 |
Why?
|
| Body Water | 1 | 2004 | 35 | 0.050 |
Why?
|
| Osmolar Concentration | 1 | 2004 | 180 | 0.050 |
Why?
|
| Transfection | 1 | 2006 | 908 | 0.050 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2004 | 84 | 0.050 |
Why?
|
| Ion Channels | 1 | 2005 | 260 | 0.050 |
Why?
|
| Pulmonary Circulation | 1 | 2004 | 92 | 0.050 |
Why?
|
| Brain | 1 | 2014 | 2482 | 0.050 |
Why?
|
| APACHE | 1 | 2003 | 24 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2004 | 159 | 0.050 |
Why?
|
| Multiple Organ Failure | 1 | 2003 | 60 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 340 | 0.050 |
Why?
|
| Exercise | 1 | 2006 | 354 | 0.050 |
Why?
|
| Likelihood Functions | 1 | 2003 | 257 | 0.050 |
Why?
|
| Thiosulfates | 1 | 2002 | 3 | 0.050 |
Why?
|
| Circadian Rhythm | 1 | 2005 | 300 | 0.050 |
Why?
|
| Fluorocarbons | 1 | 2002 | 72 | 0.050 |
Why?
|
| Mucociliary Clearance | 1 | 2001 | 7 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2003 | 509 | 0.050 |
Why?
|
| Potassium Channels | 1 | 2004 | 359 | 0.040 |
Why?
|
| Splanchnic Circulation | 1 | 2001 | 14 | 0.040 |
Why?
|
| Brain Death | 1 | 2002 | 88 | 0.040 |
Why?
|
| Stomach Ulcer | 1 | 2001 | 23 | 0.040 |
Why?
|
| Cholecystitis | 1 | 2001 | 17 | 0.040 |
Why?
|
| Incidence | 1 | 2006 | 1715 | 0.040 |
Why?
|
| Esophagitis | 1 | 2001 | 43 | 0.040 |
Why?
|
| Gastrointestinal Motility | 1 | 2001 | 26 | 0.040 |
Why?
|
| ROC Curve | 1 | 2003 | 797 | 0.040 |
Why?
|
| Atrial Fibrillation | 1 | 2006 | 392 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2004 | 531 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2001 | 109 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 847 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 2090 | 0.040 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2000 | 27 | 0.040 |
Why?
|
| Forecasting | 1 | 2001 | 317 | 0.040 |
Why?
|
| Respiratory Muscles | 1 | 2000 | 28 | 0.040 |
Why?
|
| Diarrhea | 1 | 2001 | 181 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2004 | 926 | 0.040 |
Why?
|
| Comorbidity | 1 | 2003 | 1011 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2000 | 203 | 0.040 |
Why?
|
| Genotype | 1 | 2004 | 1881 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2003 | 775 | 0.040 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2019 | 14 | 0.040 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2019 | 16 | 0.040 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2018 | 21 | 0.040 |
Why?
|
| STAT Transcription Factors | 1 | 2018 | 18 | 0.040 |
Why?
|
| Janus Kinases | 1 | 2018 | 24 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2000 | 263 | 0.040 |
Why?
|
| Intubation, Intratracheal | 1 | 2000 | 161 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2000 | 172 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 1230 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 3639 | 0.040 |
Why?
|
| National Institute of Environmental Health Sciences (U.S.) | 1 | 2018 | 3 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2004 | 943 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2000 | 314 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2000 | 323 | 0.030 |
Why?
|
| Propensity Score | 1 | 2018 | 180 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 2463 | 0.030 |
Why?
|
| Smoking | 1 | 2001 | 653 | 0.030 |
Why?
|
| Mutation | 1 | 2009 | 4374 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2019 | 399 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2009 | 3157 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1010 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2006 | 2418 | 0.030 |
Why?
|
| Rho Guanine Nucleotide Exchange Factors | 1 | 2014 | 17 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2015 | 58 | 0.030 |
Why?
|
| Genome | 1 | 2018 | 407 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2015 | 76 | 0.030 |
Why?
|
| Protective Agents | 1 | 2014 | 34 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 126 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1957 | 0.030 |
Why?
|
| Cytosol | 1 | 2012 | 198 | 0.020 |
Why?
|
| DNA Primers | 1 | 2012 | 548 | 0.020 |
Why?
|
| Trefoil Factor-1 | 1 | 2009 | 2 | 0.020 |
Why?
|
| Adolescent | 1 | 2003 | 9895 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 2344 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2009 | 417 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 2005 | 75 | 0.010 |
Why?
|
| Hypothermia, Induced | 1 | 2005 | 91 | 0.010 |
Why?
|
| Procaterol | 1 | 2001 | 1 | 0.010 |
Why?
|
| Epithelial Sodium Channels | 1 | 2001 | 7 | 0.010 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2001 | 42 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 394 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2001 | 683 | 0.010 |
Why?
|